Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.-MedSci.cn

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Ficial, M; Jegede, O; Sant'Angelo, M; Moreno, S; Braun, DA; Wind-Rotolo, M; Pignon, JC; Catalano, PJ; Sun, MXN; Van Allen, EM; Freeman, GJ; Sharpe, A; Hodi, FS; Motzer, RJ; Wu, CJ; Atkins, MB; McDermott, DF; Shukla, SA; Choueiri, TK; Signoretti, S

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

科室

工具

服务